Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy

Amy Sun; Raymond L. Lam; Amy Harman; Anna C. Pavlick; Gary A. Herman

Authors

Amy Sun
Raymond L. Lam
Amy Harman
Anna C. Pavlick
Gary A. Herman

Keywords:

Cell cycle proteins, phosphorylated CDC2, biological markers, biomarkers, proteins, Cells, chemotherapy, cancers

Abstract

This study was to clinically validate phosphorylated CDC2(pCDC2) as a biomarker for Wee1 kinase inhibitors by measuring pCDC2 in skin biopsies from patients receiving DNA damaging chemotherapy. Skin biopsies were performed at scheduled times after chemotherapy. Total CDC2 and pCDC2 in epidermal cells, hair follicle and bulb from skin biopsies were determined using chromogenic multiplex immunohis-tochemistry with multispectral image analysis. Statistical analyses were performed for each cell type after log-transformation of data. Thirty-one patients (29-88 years) completed the study. Significant induction of pCDC2 in response to chemotherapy was detected. Epidermis was most consistently evaluable across skin biopsies, demonstrating strong induction of pCDC2. The percentage of cells positive for total CDC2 and pCDC2 showed a 1.40-fold induction from baseline to 24h post-infusion (p=0.012) and a 2.05-fold increase from baseline to 48h (p

Downloads

How to Cite

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy. (2014). Global Journal of Medical Research, 14(2), 11-21. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

O. Hashimoto (2006) Cell cycle regulation by the Wee1 Inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. 6(1), 292. https://doi.org/10.1186/1471-2407-6-292

H. Hirai (2009) Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. 8(11), 2992-3000. https://doi.org/10.1158/1535-7163.mct-09-0463

H. Hirai (2010) MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. 9(7), 514-522. https://doi.org/10.4161/cbt.9.7.11115

Takumi Kawabe (2004) G2 checkpoint abrogators as anticancer drugs. 3(4), 513-519. https://doi.org/10.1158/1535-7163.513.3.4

S. Leijen, J. Beijnen, J. Schellens (2010) Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53- Deficient Tumor Cells to DNADamaging Agents. 5(3), 186-191. https://doi.org/10.2174/157488410791498824

Jun Li, Yuli Wang, Yi Sun, Theodore Lawrence (2002) Wild-Type TP53 Inhibits G2-Phase Checkpoint Abrogation and Radiosensitization Induced by PD0166285, a WEE1 Kinase Inhibitor. 157(3), 322-330. https://doi.org/10.1667/0033-7587(2002)157

S. Mizuarai (2009) Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. 8(1), 34. https://doi.org/10.1186/1476-4598-8-34

Matthew O'connell, Nancy Walworth, Antony Carr (2000) The G2-phase DNA-damage checkpoint. 10(7), 296-303. https://doi.org/10.1016/s0962-8924(00)01773-6

M. Oken (1982) Toxicity and Response: Criteria of the Eastern Cooperative Oncology Group. 5, 649-655.

S. Paul (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. 9(3), 203-214. https://doi.org/10.1038/nrd3078

W. Plunkett, P. Huang, Y. Xu, V. Heinemann, R. Grunewald, V. Gandhi (1995) Gemcitabine: metabolism, mechanisms of action, and selfpotentiation. 22, 3-10.

Geoffrey Shapiro, J. Harper (1999) Anticancer drug targets: cell cycle and checkpoint control. 104(12), 1645-1653. https://doi.org/10.1172/jci9054

D. Tan (2009) Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. 15(5), 406-420. https://doi.org/10.1097/ppo.0b013e3181bd0445

Y. Wang (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. 61, 8211-8217.

J. Yun (1999) p53 Negatively Regulates cdc2 Transcription via the CCAAT-binding NF-Y Transcription Factor. 274(42), 9677-2968. https://doi.org/10.1074/jbc.274.42.29677